AstraZeneca Backs FY26 Revenue Growth Guidance
AstraZeneca reaffirmed its FY26 revenue growth outlook at up mid-to-high single-digit percentage.
Related stories
US Stocks Sharply Lower as Amazon and Intel Sink
Stocks in the US were lower on Friday, with the S&P 500 losing 0.3%, the Nasdaq tumbling 2.4% and the Dow Jones decreasing 185 points, weighed by a sell-off in the tech sector, fol
H impact | EARNINGS | Oct 30, 2026, 01:47 PM UTC
Brazilian Stocks Head for Fifth Straight Decline
The Ibovespa fell nearly 1% to hover below 168,000 on Friday, hitting a more than three-month low and heading for a fifth consecutive decline amid fiscal uncertainty and Vale’s wea
L impact | EARNINGS | Oct 30, 2026, 01:41 PM UTC
Alliant Energy Reports Q3 2026 EPS of $1.52 and 2027 Guidance
Alliant Energy reported third-quarter 2026 GAAP EPS of $1.52, up from $1.09 a year earlier. Nine-month EPS was $3.04, up 17% from $2.59; the company also provided 2027 guidance.
M impact | EARNINGS | Oct 30, 2026, 01:33 PM UTC
Imperial Oil reports higher Q3 net income; dividend unchanged
Imperial Oil reported higher net income for the third quarter and declared an unchanged quarterly dividend.
M impact | EARNINGS | Oct 30, 2026, 01:30 PM UTC
US stock futures fell for a second day as another batch of disappointing tech earnings fuelled the sector's selloff, with investors increasingly questioning the return on massive artificial intelligence spending as signs emerged that America's technology behemoths' core businesses are losing momentum. Crude oil rose.
US stock futures fell for a second day as another batch of disappointing tech earnings fuelled the sector's selloff, with investors increasingly questioning the return on massive a
H impact | EARNINGS | Oct 30, 2026, 01:16 PM UTC
Qualcomm Q4 2026 Earnings
H impact | EARNINGS | Oct 30, 2026, 01:15 PM UTC